Literature DB >> 17924058

Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.

Marcello Esposito, P Penza, G Orefice, A Pagano, E Parente, A Abbadessa, V Bonavita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17924058     DOI： 10.1007/s11060-007-9479-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  9 in total

Review 1.  B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2006-04-27       Impact factor: 12.310

2.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

Authors:  P Trouillas; T Takayanagi; M Hallett; R D Currier; S H Subramony; K Wessel; A Bryer; H C Diener; S Massaquoi; C M Gomez; P Coutinho; M Ben Hamida; G Campanella; A Filla; L Schut; D Timann; J Honnorat; N Nighoghossian; B Manyam
Journal:  J Neurol Sci       Date:  1997-02-12       Impact factor: 3.181

3.  An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.

Authors:  Setareh Shams'ili; Janet de Beukelaar; Jan Willem Gratama; Herbert Hooijkaas; Martin van den Bent; Mars van 't Veer; Peter Sillevis Smitt
Journal:  J Neurol       Date:  2006-01       Impact factor: 4.849

Review 4.  Update on paraneoplastic syndromes.

Authors:  Edward J Dropcho
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

Review 5.  Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Authors:  M D Pescovitz
Journal:  Am J Transplant       Date:  2006-05       Impact factor: 8.086

6.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

7.  Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Authors:  Steven Vernino; Brian Patrick O'Neill; Randolph S Marks; Judith R O'Fallon; David W Kimmel
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

8.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

Authors:  Setareh Shams'ili; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Herbert Hooijkaas; Bronno van der Holt; Charles Vecht; Peter Sillevis Smitt
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

9.  Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy.

Authors:  Peter Sillevis Smitt; Joost Grefkens; Bertie de Leeuw; Martin van den Bent; Wim van Putten; Herbert Hooijkaas; Charles Vecht
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849
  9 in total
  11 in total

1.  Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration.

Authors:  J Schessl; M Schuberth; P Reilich; P Schneiderat; N Strigl-Pill; M C Walter; B Schlotter-Weigel; B Schoser
Journal:  J Neurol       Date:  2010-12-21       Impact factor: 4.849

2.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

3.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

4.  Treatment of paraneoplastic neurologic disorders.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

5.  Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.

Authors:  J Honnorat
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Paraneoplastic movement disorders.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

7.  Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.

Authors:  Francisco Coret; Isabel Bosca; Loren Fratalia; Jaume Perez-Griera; Ana Pascual; Bonaventura Casanova
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

Review 8.  Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.

Authors:  Malcolm Proudfoot; Alastair Wilkins
Journal:  Curr Treat Options Neurol       Date:  2017-11-25       Impact factor: 3.598

Review 9.  What is the Etiology of Dysarthria and Ataxia in a Woman With Cancer?

Authors:  Paula J Anastasia
Journal:  J Adv Pract Oncol       Date:  2014-03

10.  Treatment of paraneoplastic cerebellar degeneration.

Authors:  John E Greenlee
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.